Skip to main content
. 2020 Mar 24;13:881–891. doi: 10.2147/IDR.S245991

Table 3.

Multivariable Stratified Cox Regression Analysis for Incidence of Mortality Among VL Patients at the University of Gondar Hospital, 2019

Variables Death Hazard Ratio (95% CI)
No N (%) Yes N (%) CHR AHR
Age Median= 27 1.04 (1.01–1.07) 0.99 (0.95–1.04)
VL episode
 Primary 504 (89.8) 57 (10.2) 1 1
 Relapse 17 (68) 8 (32) 3.98 (1.89–8.36) 3.03 (1.25–7.35)*
Hemoglobin (mg/dl)
 0–7.9 218 (85.5) 37 (14.5) 1.59 (0.71–3.57) 1.42 (0.59–3.42)
 8–10.9 232 (91.7) 21 (8.3) 0.87 (0.37–2.05) 1.06 (0.42–2.56)
 ≥11 71 (91.0) 7 (8.9) 1 1
Illness Duration (days)
 ≤30 300 (91.5) 28 (8.5) 1 1
 >30 221 (85.7) 37 (14.3) 1.64 (1.01–2.69) 0.92 (0.51–1.64)
Treatment Toxicity
 No 507 (93) 38 (7) 1 1
 Yes 14 (34.1) 27 (65.9) 13.99 (8.48–23.10) 5.87 (3.3–10.44)*
Comorbidity
 No 395 (94.7) 22 (5.3) 1 1
 Yes 126 (74.6) 43 (25.4) 5.57 (3.33–9.32) 2.29 (1.27–4.11)*
Diarrhea
 No 482 (90.1) 53 (9.9) 1 1
 Yes 39 (76.5) 12 (23.5) 2.61 (1.39–4.89) 1.73 (0.88–3.78)
Nasal Bleeding
 No 459 (92.3) 38 (7.7) 1 1
 Yes 62 (69.7) 27 (30.3) 4.51 (2.75–7.39) 2.58 (1.48–4.51)*
Edema
 No 443 (90.8) 45 (9.2) 1 1
 Yes 78 (79.6) 20 (20.4) 2.34 (1.38 −3.97) 1.45 (0.78–2.66)
Jaundice
 No 465 (92.0) 40 (8.0) 1 1
 Yes 56 (69.1) 25 (30.9) 4.62 (2.79–7.62) 2.84 (1.57–5.16)*
Creatinine Level (mg/dl)
 <1.5 455 (91.0) 45 (9.0) 1 1
 ≥1.5 66 (76.7) 20 (27.3) 2.88 (1.70–4.88) 1.33 (0.70–2.54)
Condition of Patient
 Ambulatory 456 (94.4) 27 (5.6) 1 1
 Bedridden 65 (63.1) 38 (36.9) 8.29 (5.05–13.59) 3.26 (1.86–5.73)*
Parasite Load
 Low 469 (90.4) 50 (9.6) 1 1
 High 52 (77.6) 15 (22.4) 2.29 (1.28–4.10) 1.94 (0.97–3.89)
Treatment Type
 SSG and PM 398 (93.7) 27 (6.3) 1 1
 SSG 69 (83.1) 14 (16.9) 2.16 (1.07–4.34) 0.81 (0.37–1.78)
 Ambisome 54 (69.2) 24 (30.8) 7.82 (4.39–13.89) 1.79 (0.91–3.54)

Note: *p<0.05.

Abbreviations: SSG, sodium stibogluconate; PM, paromomycin.